Tags

Type your tag names separated by a space and hit enter

[Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
Clin Calcium. 2010 Nov; 20(11):1700-8.CC

Abstract

Hyperphosphatemia with decline of kidney function has been associated with increased mortality and the development of cardiovascular calcification. Sevelamer hydrochloride was the first synthetic non-aluminum and calcium-free phosphate binder commercially available. Sevelamer is as effective as calcium-based binders in lowering phosphate, but without the tendency to promote hypercalcemia. There is some evidence that sevelamer hydrochloride can attenuate cardiovascular calcification compared with calcium-based phosphate binders. Furthermore, sevelamer has several additional pleiotropic effects that may extend its basic indication, some of which may help attenuate vascular calcification. These includes effects on lipid metabolism, and systemic inflammatory response.

Authors+Show Affiliations

Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine.No affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

jpn

PubMed ID

21037391

Citation

Koizumi, Masahiro, and Masafumi Fukagawa. "[Treatment of Hyperphosphatemia With Sevelamer Hydrochloride in CKD Patients: Effects On Vascular Calcification and Mortality]." Clinical Calcium, vol. 20, no. 11, 2010, pp. 1700-8.
Koizumi M, Fukagawa M. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality]. Clin Calcium. 2010;20(11):1700-8.
Koizumi, M., & Fukagawa, M. (2010). [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality]. Clinical Calcium, 20(11), 1700-8. https://doi.org/CliCa101117001708
Koizumi M, Fukagawa M. [Treatment of Hyperphosphatemia With Sevelamer Hydrochloride in CKD Patients: Effects On Vascular Calcification and Mortality]. Clin Calcium. 2010;20(11):1700-8. PubMed PMID: 21037391.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality]. AU - Koizumi,Masahiro, AU - Fukagawa,Masafumi, PY - 2010/11/2/entrez PY - 2010/11/3/pubmed PY - 2011/2/4/medline SP - 1700 EP - 8 JF - Clinical calcium JO - Clin Calcium VL - 20 IS - 11 N2 - Hyperphosphatemia with decline of kidney function has been associated with increased mortality and the development of cardiovascular calcification. Sevelamer hydrochloride was the first synthetic non-aluminum and calcium-free phosphate binder commercially available. Sevelamer is as effective as calcium-based binders in lowering phosphate, but without the tendency to promote hypercalcemia. There is some evidence that sevelamer hydrochloride can attenuate cardiovascular calcification compared with calcium-based phosphate binders. Furthermore, sevelamer has several additional pleiotropic effects that may extend its basic indication, some of which may help attenuate vascular calcification. These includes effects on lipid metabolism, and systemic inflammatory response. SN - 0917-5857 UR - https://www.unboundmedicine.com/medline/citation/21037391/[Treatment_of_hyperphosphatemia_with_sevelamer_hydrochloride_in_CKD_patients:_effects_on_vascular_calcification_and_mortality]_ L2 - https://medlineplus.gov/vasculardiseases.html DB - PRIME DP - Unbound Medicine ER -